Table 5. Additive hazard ratios of probable Alzheimer's disease development among ε4 carriers reporting depression within the last 2 years of baseline.

Predictor variables	Sample size with AD endpoint	Depression—last 2 years × ε4 Main effects (unadjusted) Hazard ratio (95% CI)	Depression—last 2 years × ε4 Main effects adjusteda Hazard ratio (95% CI)	Depression last 2 years Main effects adjusted with AD medication use Hazard ratio (95% CI)
Depression—last 2 years × ε4 carrier	455	4.65 (3.24–6.68)**	6.41 (4.43–9.29)**	3.03 (2.06–4.47)**
Use of antidepressant	90	4.24 (1.95–9.23)**	6.90 (3.02–15.80)**	3.19 (1.37–7.43)*
Did not use antidepressant		3.26 (1.81–5.86)**	3.93 (2.14–7.24)**	2.85 (1.54–5.29)**
Bupropion use	9	1.68 (0.186–15.16)	4.21 (0.368–48.12)	3.76 (0.233–60.71)
No bupropion use		4.70 (3.23–6.83)**	6.30 (4.29–9.24)**	3.05 (2.04–4.56)**
Citalopram use	25	8.77 (1.14–67.28)*	14.78 (1.87–116.63)*	6.84 (0.806–58.08)
No citalopram use		3.67 (2.44–5.54)**	5.02 (3.30–7.65)**	2.57 (1.66–3.98)**
Escitalopram use	17	0.841 (0.166–4.27)	1.51 (0.290–7.87)	0.339 (0.050–2.28)
No escitalopram use		4.79 (3.30–6.96)**	6.52 (4.45–9.55)**	3.22 (2.16–4.79)**
Fluoxetine use	2	—	—	—
No fluoxetine use		4.84 (3.36–6.97)**	6.55 (4.51–9.51)**	3.08 (2.08–4.55)**
Mirtazapine use	9	—	—	—
No mirtazapine use		4.63 (3.21–6.69)**	6.40 (4.39–9.33)**	3.01 (2.03–4.46)**
Paroxetine use	7	4.44 (0.480–41.01)	3.68 (0.316–42.83)	2.99 (0.245–36.32)
No paroxetine use		4.38 (3.01–6.37)**	6.08 (4.14–8.97)**	2.83 (1.90–4.22)**
Sertraline use	10	1.58 (0.143–17.49)	—	—
No sertraline use		4.98 (3.44–7.20)**	6.97 (4.78–10.17)**	3.42 (2.31–5.07)**
Trazodone use	12	5.05 (0.457–55.90)	9.63 (0.819–113.21)	4.62 (0.343–62.18)
No trazodone use		4.66 (3.22–6.73)**	6.39 (4.38–9.32)**	3.07 (2.07–4.56)**

^—indicates sample size too small for analysis.

^aAdjusted for sex, age, education, and race.

^*Statistical significance at p < 0.05.

^**p < 0.001.